Last week, biosimilar developer Coherus BioSciences announced that it has reached a settlement with innovator drug maker Amgen over a trade secret case that was pending in the Superior Court of California. Separately, Amgen filed a new complaint against biosimilar developer Samsung Bioepis.
Last week, biosimilar developer Coherus BioSciences announced that it has reached a settlement with innovator drug maker Amgen over a trade secret case that was pending in the Superior Court of California. The case revolved around trade secrets related to Amgen’s innovator pegfilgrastim, Neulasta.
In a lawsuit filed in 2017, Amgen claimed that Coherus had engineered a conspiracy to steal its trade secrets relevant to Neulasta when it was seeking to develop its pegfilgrastim biosimilar, Udenyca; the alleged conspiracy included recruiting Amgen’s employees to work for Coherus, said Amgen, and the receipt of sensitive information related to, among other aspects of its business, Amgen’s operating procedures, analytical methods, contracting strategies.
Coherus denied the accusations at the time, and suggested that the lawsuit was, as Chief Executive Officer Denny Lanfear said in a 2017 statement, “best understood as an effort by Amgen to use baseless litigation in an effort to delay Coherus as a competitor in the pegfilgrastim market.”
In its May 2 announcement, Coherus said that, while the details of the settlement reached in the case are confidential, Coherus will continue to market its FDA-approved Udencya and will pay a “mid-single digit royalty” to Amgen for the next 5 years.
“This settlement allows us to put this matter behind us and fully focus on the robust launch we have underway,” said Lanfear in a statement.
Separately, Amgen filed a new complaint against biosimilar developer Samsung Bioepis. This action relates to the newly approved etanercept biosimilar, Eticovo, which references Amgen’s innovator etanercept, Enbrel.
The complaint, filed by Amgen, Hoffman-La Roche, and Immunex in the District Court of New Jersey, alleges infringement of 5 patents under the Biologics Price Competition and Innovation Act (BPCIA).
The complaint also states that Samsung Bioepis did not comply with the requirements of the BPCIA by failing to provide relevant information, such as a copy of its application for the drug and 180-day commercial marketing notification, for the drug.
Amgen, Hoffman-La Roche, and Immunex have asked the court to enter a judgment in their favor, to issue a restraining order to keep Samsung Bioepis from making or selling the biosimilar, and a preliminary injunction restricting making or selling the biosimilar until 180 days after Samsung Bioepis provides its notice of commercial marketing and until the suit has concluded. The complainants have also demanded a jury trial in the case.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.